Treatment-specific risks of second malignancy and cardiovascular disease in Hodgkin lymphoma survivors.

9584 Background: Hodgkin lymphoma (HL) survivors are at increased risk to develop late treatment-related complications, including second malignant neoplasms (SMNs) and cardiovascular disease (CVD). Research to date has focused on separate risk estimates and therefore, we aimed to assess the combined risk of developing SMN and/or CVD. Methods: Our multicenter cohort comprised 2,480 5-year HL survivors, treated before age 51 between 1965 and 1995. CVD endpoints (coronary heart disease [CHD], cardiomyopathy and congestive heart failure [HF], and valvular heart disease) were assessed through general practitioners. Data on SMN were derived from linkage with the Netherlands Cancer Registry. Standardized incidence ratios (SIRs) were estimated to compare SMN and CVD risk with the general population. Cumulative incidences of SMN and/or CVD were calculated with death from other causes as competing risk. Treatment-specific risks of developing SMN and/or CVD were quantified using Cox regression analysis. Results: Aft...